AdvanSix Inc. (ASIX) Balance Sheet

The equity base has been broadly flat despite retained earnings declining from about $677M in Q2 2025 to $630M in Q3 2026, which is consistent with recent operating losses reducing accumulated profits. Total liabilities climbed from $731M to $892M over the period, so the balance sheet expansion appears leverage-assisted rather than earnings-driven. Investors should monitor whether the liability growth reflects working capital needs or structural borrowing.

The recent paydown lowers leverage meaningfully, which may indicate management prioritized deleveraging after weaker operating performance. However, the D/E ratio still sits well above where it stood in 2024 at roughly 0.40 to 0.45, so the cushion is improved rather than wide. Whether the reduction was funded by operating cash or asset sales is not clear from the supplied balance sheet data alone and warrants further investigation.

Cash balances have remained small relative to total assets of roughly $1.7B, which suggests the company relies on operating inflows and revolving access rather than a large reserve. A current ratio near 1.2 is adequate but not generous for a cyclical chemicals producer facing margin compression. The low cash level makes the business sensitive to any further working capital outflow.

The step-up in net PP&E is consistent with continued capital reinvestment, which aligns with the roughly 7 percent of revenue capital spending noted in prior cash flow findings. Goodwill at $56.2M is modest relative to $1.7B in assets, so impairment risk on the balance sheet appears limited. The heavy fixed asset base means returns depend on sustaining utilization through commodity cycles.